semaglutide injections for weight management FDA approves obesity drug that helped people cut 15% Semaglutide: A Breakthrough in Personalized

CagriSema (Cagrilintide + Semaglutide) CagriSema is a co-formulated combination therapy containing 2.4 mg each of Cagrilintide (a long-acting amylin analog) and Semaglutide (a GLP-1 receptor agonist), administered as a single weekly subcutaneous injection

$186/mo tirz (12-mo) , $190 (6-mo), $195 (3-mo), $215 (monthly)

Under dietetic guidance, an intake of approximately 1.0 to 1.2 grams per kilogram of body weight daily may be appropriate, particularly for older adults or those losing weight

It induces a clinical syndrome mimicking acute ethanol intoxication, characterized by confusion, ataxia, slurred speech, and unprovoked hostility

22% of American adults said they found the cost very difficult to manage, with a similar share among insured users (23%)